These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35112378)

  • 21. Observed efficacy and clinically important improvements in participants with osteoarthritis treated with subcutaneous tanezumab: results from a 56-week randomized NSAID-controlled study.
    Neogi T; Hunter DJ; Churchill M; Shirinsky I; White A; Guermazi A; Omata M; Fountaine RJ; Pixton G; Viktrup L; Brown MT; West CR; Verburg KM
    Arthritis Res Ther; 2022 Mar; 24(1):78. PubMed ID: 35351194
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics and Immunogenicity of Frunevetmab in Osteoarthritic Cats Following Intravenous and Subcutaneous Administration.
    Walters RR; Boucher JF; De Toni F
    Front Vet Sci; 2021; 8():687448. PubMed ID: 34179175
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebo-controlled study.
    Nagashima H; Suzuki M; Araki S; Yamabe T; Muto C;
    Osteoarthritis Cartilage; 2011 Dec; 19(12):1405-12. PubMed ID: 22004765
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period.
    Berenbaum F; Blanco FJ; Guermazi A; Miki K; Yamabe T; Viktrup L; Junor R; Carey W; Brown MT; West CR; Verburg KM
    Ann Rheum Dis; 2020 Jun; 79(6):800-810. PubMed ID: 32234715
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety.
    Markman JD; Bolash RB; McAlindon TE; Kivitz AJ; Pombo-Suarez M; Ohtori S; Roemer FW; Li DJ; Viktrup L; Bramson C; West CR; Verburg KM
    Pain; 2020 Sep; 161(9):2068-2078. PubMed ID: 32453139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial.
    Balanescu AR; Feist E; Wolfram G; Davignon I; Smith MD; Brown MT; West CR
    Ann Rheum Dis; 2014 Sep; 73(9):1665-72. PubMed ID: 23852695
    [TBL] [Abstract][Full Text] [Related]  

  • 27. From the Cover: Evaluation of the Effects of Tanezumab, a Monoclonal Antibody Against Nerve Growth Factor, on the Sympathetic Nervous System in Adult Cynomolgus Monkeys (Macaca fascicularis): A Stereologic, Histomorphologic, and Cardiofunctional Assessment.
    Belanger P; Butler P; Butt M; Bhatt S; Foote S; Shelton D; Evans M; Arends R; Hurst S; Okerberg C; Cummings T; Potter D; Steidl-Nichols J; Zorbas M
    Toxicol Sci; 2017 Aug; 158(2):319-333. PubMed ID: 28525647
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tanezumab for chronic low back pain: a long-term, randomized, celecoxib-controlled Japanese Phase III safety study.
    Konno SI; Nikaido T; Markman JD; Ohta M; Machida T; Isogawa N; Yoshimatsu H; Viktrup L; Brown MT; West CR; Verburg KM
    Pain Manag; 2022 Apr; 12(3):323-335. PubMed ID: 34786956
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I-III Clinical Trials.
    Suleiman AA; Minocha M; Khatri A; Pang Y; Othman AA
    Clin Pharmacokinet; 2019 Oct; 58(10):1309-1321. PubMed ID: 31054118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Onset and maintenance of efficacy of subcutaneous tanezumab in patients with moderate to severe osteoarthritis of the knee or hip: A 16-week dose-titration study.
    Schnitzer TJ; Khan A; Bessette L; Davignon I; Brown MT; Pixton G; Prucka WR; Tive L; Viktrup L; West CR
    Semin Arthritis Rheum; 2020 Jun; 50(3):387-393. PubMed ID: 32252976
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of subcutaneous tanezumab in patients with knee or hip osteoarthritis.
    Birbara C; Dabezies EJ; Burr AM; Fountaine RJ; Smith MD; Brown MT; West CR; Arends RH; Verburg KM
    J Pain Res; 2018; 11():151-164. PubMed ID: 29386912
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of Various Dosages and Administration Methods of Tanezumab for the Treatment of Pain in Knee and Hip Osteoarthritis: a Network Meta-Analysis.
    Cai YZ; Nie LY; Ruan JQ; Zhao K
    Clin Ther; 2021 Dec; 43(12):2116-2126. PubMed ID: 34819241
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and Pharmacodynamics of JNJ-55920839, an Antibody Targeting Interferon α/ω, in Healthy Subjects and Subjects with Mild-to-Moderate Systemic Lupus Erythematosus.
    Yao Z; Loggia L; Fink D; Chevrier M; Marciniak S; Sharma A; Xu Z
    Clin Drug Investig; 2020 Dec; 40(12):1127-1136. PubMed ID: 33085033
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained?
    Berenbaum F; Langford R; Perrot S; Miki K; Blanco FJ; Yamabe T; Isogawa N; Junor R; Carey W; Viktrup L; West CR; Brown MT; Verburg KM
    Eur J Pain; 2021 Aug; 25(7):1525-1539. PubMed ID: 33728717
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tanezumab for the treatment of pain from osteoarthritis of the knee.
    Lane NE; Schnitzer TJ; Birbara CA; Mokhtarani M; Shelton DL; Smith MD; Brown MT
    N Engl J Med; 2010 Oct; 363(16):1521-31. PubMed ID: 20942668
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population Pharmacokinetics of Fasinumab in Healthy Volunteers and Patients With Pain Due to Osteoarthritis of the Knee or Hip.
    Lin KJ; Turner KC; Hassan HE; Harnisch LO; Davis JD; DiCioccio AT
    Clin Pharmacol Drug Dev; 2024 Jun; 13(6):621-630. PubMed ID: 38323727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population Pharmacokinetic Modeling of Benralizumab in Adult and Adolescent Patients with Asthma.
    Yan L; Wang B; Chia YL; Roskos LK
    Clin Pharmacokinet; 2019 Jul; 58(7):943-958. PubMed ID: 30854591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of intravenous tanezumab for the symptomatic treatment of osteoarthritis: 2 randomized controlled trials versus naproxen.
    Ekman EF; Gimbel JS; Bello AE; Smith MD; Keller DS; Annis KM; Brown MT; West CR; Verburg KM
    J Rheumatol; 2014 Nov; 41(11):2249-59. PubMed ID: 25274899
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nerve Growth Factor Antagonists: Is the Future of Monoclonal Antibodies Becoming Clearer?
    Bannwarth B; Kostine M
    Drugs; 2017 Sep; 77(13):1377-1387. PubMed ID: 28660479
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tanezumab: a selective humanized mAb for chronic lower back pain.
    Webb MP; Helander EM; Menard BL; Urman RD; Kaye AD
    Ther Clin Risk Manag; 2018; 14():361-367. PubMed ID: 29503555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.